<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002996</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065544</org_study_id>
    <secondary_id>E1Z95</secondary_id>
    <nct_id>NCT00002996</nct_id>
  </id_info>
  <brief_title>Flecainide in Treating Patients With Chronic Neuropathic Pain</brief_title>
  <official_title>Flecainide for the Treatment of Chronic Neuropathic Pain: A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Flecainide therapy may help patients with neuropathic pain live more comfortably.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of flecainide in treating patients with&#xD;
      chronic neuropathic pain from cancer or AIDS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Investigate the effectiveness of flecainide in the management of neuropathic pain.&#xD;
&#xD;
      OUTLINE: Patients are given a brief pain inventory (BPI) form to assess their pain upon&#xD;
      enrollment in the study. Following a 7 day stabilization period, flecainide is administered.&#xD;
      One capsule of flecainide is given twice a day on days 8-10, two capsules are given twice a&#xD;
      day on days 11-14 and three capsules are given twice a day on days 15-21. BPI forms are&#xD;
      completed on days 8, 15 and 22 to assess neuropathic pain.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 7-20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flecainide acetate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Chronic neuropathic pain with diagnosis of cancer or AIDS&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinical history of infarction or angina&#xD;
&#xD;
          -  No advanced heart failure&#xD;
&#xD;
          -  No sick sinus syndrome, intraventricular conduction disease, second or third degree AV&#xD;
             block or arrhythmias requiring treatment (exception may be granted by cardiac consult)&#xD;
&#xD;
          -  No focal wall motion abnormalities&#xD;
&#xD;
          -  Ejection fraction at least 40%&#xD;
&#xD;
          -  Systolic blood pressure at least 90 mm Hg&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Must be able to take oral medication&#xD;
&#xD;
          -  No known allergy or adverse reaction to flecainide, mexilitene or any other type I&#xD;
             antiarrhythmic drug&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy that may cause neuropathy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 2 weeks since prior corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No tricyclic antidepressant treatment within past 2 weeks&#xD;
&#xD;
          -  No concurrent use of flecainide, mexiletene or any other type I antiarrhythmic drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles F. Von Gunten, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Cedar Rapids Oncology Project</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403-1206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kalamazoo</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Sioux Community Cancer Consortium</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>von Gunten CF, Eappen S, Cleary JF, Taylor SG 4th, Moots P, Regevik N, Cleeland C, Cella D. Flecainide for the treatment of chronic neuropathic pain: a Phase II trial. Palliat Med. 2007 Dec;21(8):667-72. doi: 10.1177/0269216307083031.</citation>
    <PMID>18073252</PMID>
  </results_reference>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 26, 2010</last_update_submitted>
  <last_update_submitted_qc>January 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Group Chair</name_title>
    <organization>Eastern Cooperative Oncology Group</organization>
  </responsible_party>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

